Exploring New Growth Opportunities through Partnerships and M&A
First written in FY2016. 17 of 22 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
72 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The group agreed to acquire, for €150 million, the drug product manufacturing plant owned by WuXi Biologics, a contract development and manufacturing organization (CDMO), in Leverkusen, Germany, and entered into a transfer agreement on 14 May 2025. Under this agreement, the acquisition was completed on 30 September 2025.」
Regarding the exploration of growth opportunities through partnerships and M&A, the company completed the acquisition of the German CDMO plant and also completed the acquisition of OrganOx as a wholly owned subsidiary. - FY2026-H1AdvancedAnnual report
「Under this agreement, the acquisition was completed on 30 September 2025. In addition, at a meeting of the Board of Directors held on 20 August 2025, the company resolved to acquire all shares of OrganOx Limited, an innovator in organ preservation devices headquartered in the United Kingdom, for a total consideration of approximately US$1.5 billion and make it a wholly owned subsidiary. On 23 August 2025, the company entered into a definitive agreement with OrganOx Limited and its shareholders. Under this agreement, the acquisition of the shares was completed on 29 October 2025, and OrganOx Limited became a wholly owned subsidiary of the company.」
Regarding the exploration of growth opportunities through M&A, the company completed the acquisition of WuXi Biologics’ German plant and also completed the acquisition of OrganOx as a wholly owned subsidiary. - FY2024AdvancedAnnual report
「MedCom provides smartphone services to medical institutions and develops and supplies applications that promote work-style reform in healthcare settings. Through this capital and business alliance, the companies will jointly develop and propose solutions to medical institutions that support work-style reform among healthcare professionals and promote team-based care.」
The exploration of growth opportunities through partnerships and M&A was given concrete form through the joint development and proposal of digital solutions for medical institutions under a capital and business alliance with MedCom. - FY2023AdvancedAnnual report
「The combination product “G-Lasta® Subcutaneous Injection 3.6 mg BodyPod,” jointly developed with Kyowa Kirin Co.,Ltd., was launched in Japan.」
As part of its policy of using partnerships and joint development as a means of growth, the company launched a combination product with Kyowa Kirin Co.,Ltd. in Japan. The partnership combining a drug and a device progressed to the commercialization stage. - FY2023-Q3RestatedAnnual report
「In Japan, although the recovery in medical demand was delayed by the impact of the eighth wave of COVID-19, the Pharmaceutical Solutions business, which partners with pharmaceutical companies, and the surgical field of the Hospital Care Solutions business performed strongly, resulting in a 1.3% increase in revenue year on year.」
The Pharmaceutical Solutions business, including partnerships with pharmaceutical companies, continued to contribute to business growth. No new acquisitions or partnership agreements were decided, and the growth policy leveraging partnerships was merely reaffirmed. - FY2022AdvancedAnnual report
「The company newly began collaborating with CSL Plasma in the collection of source plasma.」
As part of its policy of using partnerships as a means of growth, the company began collaborating with CSL Plasma on source plasma collection and entered the stage of advancing the provision of comprehensive solutions, including Rika, an IT platform and on-site support. - FY2022-Q3AdvancedAnnual report
「The alliance business also continued to expand. Global revenue increased 7.5% year on year to ¥138.7 billion.」
The alliance business, including partnerships with pharmaceutical companies, continued to expand, and global revenue in the Hospital Company increased 7.5% year on year. - FY2022-Q2AdvancedAnnual report
「In Japan, in addition to the expansion of the alliance business through partnerships with pharmaceutical companies, infusion pumps and syringe pumps in the Hospital Systems business performed strongly.」
The company continued to identify the expansion of its partnership business with pharmaceutical companies as a means of growth, while revenue in the Hospital Company increased 12.4% year on year. - FY2021AdvancedAnnual report
「Specifically, the company will consider supporting physicians in determining treatment plans tailored to individual patients through the use of data, including through strategic partnerships and acquisitions involving digital health companies.」
The exploration of growth opportunities through partnerships and acquisitions was given concrete form through collaboration with and acquisitions of digital health companies, as well as support for personalized medicine through the use of data. - FY2021-Q3AdvancedAnnual report
「Contingent consideration arising from business combinations relates to the acquisition of the large-bore hemostasis device business from Medion BioDesign Co., Ltd., the acquisition of shares in 易生科技（北京）有限公司, and the acquisition of shares in Q'lem Medical B.V., which became a wholly owned subsidiary during the first 9 months of the fiscal year.」
As part of its policy of using partnerships and M&A, the company made Q'lem Medical B.V. a wholly owned subsidiary during the first 9 months of the fiscal year. - FY2020AdvancedAnnual report
「November 2019: Acquired Aortica Corp. in the United States.」
As part of its policy of pursuing partnerships and M&A as a means of growth, the company acquired アオルティカCorp., which develops stent-graft design software and supplies covered stents. - FY2020-Q3AdvancedAnnual report
「In addition to strong performance by the spray-type adhesion barrier AdSpray and the anesthetic analgesic fentanyl injection in the Hospital Systems Business, alliance business with pharmaceutical companies expanded. As a result, Hospital Company's revenue was ¥127.8 billion, up 1.5% year on year.」
Alliance business with pharmaceutical companies expanded, and Hospital Company revenue increased 1.5% year on year. - FY2020-Q2RestatedAnnual report
「In addition to strong performance by infusion pumps and syringe pumps in the Hospital Systems Business, the spray-type adhesion barrier AdSpray and the antipyretic analgesic Acelio, alliance business with pharmaceutical companies expanded. As a result, Hospital Company's revenue was ¥82.8 billion, up 2.0% year on year.」
The company continued to describe the expansion of alliance business with pharmaceutical companies, and Hospital Company revenue increased 2.0% year on year. - FY2019-Q3AdvancedAnnual report
「The company carried out this acquisition to enter the Chinese market, where the importance of locally manufactured products is increasing, with DES products from Essent Technology, and to expand its catheter business.」
The company acquired Essent Technology, a Chinese company that develops, manufactures, and sells DES products, thereby giving concrete form to its strategy of expanding its catheter business in China through M&A. The acquisition date was 29 December 2018, and the acquisition ratio of voting equity interests was 100%. - FY2018-Q1AdvancedAnnual report
「Overseas, Cardiovascular Company recorded revenue growth across all its businesses—TIS (catheters), neurovascular, CV, and vascular—partly due to the revenue contribution from businesses and products acquired in the previous fiscal year, including the hemostasis device business.」
With regard to its policy of using acquisitions as a growth driver, the company described the contribution of businesses and products acquired in the previous fiscal year to revenue in the current quarter and revenue growth across multiple Cardiovascular Company businesses. - FY2017AdvancedAnnual report
「In the TIS Business, the company will steadily expand sales of the acquired hemostasis devices and seek further revenue growth across its access device portfolio.」
With regard to its policy of using M&A as a growth driver, the company positioned expanding sales following completion of the hemostasis device business acquisition and integration following completion of the Bolton Medical acquisition as its next growth initiatives. - FY2017-Q3AdvancedAnnual report
「On 7 December, the company entered into agreements with St. Jude Medical and Abbott to acquire their femoral artery access-site closure device businesses and related operations.」
With regard to its policy of utilizing alliances and M&A, the company entered into an agreement on 7 December 2016 to acquire the catheter-related businesses of St. Jude Medical and Abbott. - FY2017-Q2AdvancedAnnual report
「The company agreed with St. Jude Medical, Inc. and Abbott Laboratories of the United States on the basic terms for acquiring their endovascular catheter-related business. The planned acquisition price is US$1.12 billion.」
With regard to its policy of utilizing alliances and M&A, the company disclosed concrete progress consisting of an agreement on the basic terms for acquiring an endovascular catheter-related business and a planned acquisition price of US$1.12 billion. - FY2017-Q1AdvancedAnnual report
「Terumo Americas Holding, Inc. entered into an agreement on 12 June 2016 to acquire all shares of Sequent Medical, Inc. of California, USA.」
With regard to its policy of utilizing alliances and M&A, the company made concrete progress by entering into an agreement to acquire all shares of Sequent Medical. - FY2016First statedAnnual report
「In addition to pursuing growth in existing businesses, the company will continue to explore new growth opportunities and seek to strengthen its competitiveness as a global company by utilizing alliances and M&A where synergies are expected with the technologies and products in which the Group has strengths.」
The company has indicated a policy of using alliances and M&A based on potential synergies with its technologies and products, in addition to growth in existing businesses.